Developing therapeutic cancer vaccines

Press releases & announcements

17 January, 2019

RhoVac reports positive interim immune-results in the follow-up phase of company’s phase I/II clinical study

RhoVac AB (“RhoVac”) reported today, 17th January 2019, positive interim immune-results on 3- and 6-month’s follow-up testing in their phase I/II clinical study RhoVac-001 in prostate cancer patients. In the... [Read more]

17 December, 2018

RhoVac announces that the first patient completed the follow-up phase of the clinical phase I / II study

RhoVac AB (“RhoVac”) announce today, 17th December 2018, that the first prostate cancer patient included in the clinical phase I / II study with RhoVac’s drug candidate RV001 has completed... [Read more]

14 November, 2018

RhoVac participates in international business conferences in the UK and the United States

RhoVac AB (“RhoVac”) will participate in J.P. Morgan Healthcare Conference in San Francisco, USA in January 2019 and at the Jefferies London Healthcare Conference, UK, 14-15 November 2018. From 7th... [Read more]

Press Releases and Company Announcements published before 1 May 2017 in Swedish only.

RhoVac in Brief

RhoVac undertakes research and development of therapeutic cancer vaccines. The primary candidate, RV001, targets RhoC which is overexpressed in cancer cells with metastatic potential.

Because most cancers form metastases, RV001 can potentially be used to treat a broad range of cancers. RhoVac's concept focuses on eliminating metastatic cancer cells that may escape treatment of the parent tumour via other methods. Because RhoC is not expressed in the parent tumour, the company goal is to use the developed product in combination with another therapy -- specifically, treatment of the parent tumour by e.g. surgery, radiotherapy or chemotherapy together with treatment with the therapeutic cancer vaccine to combat metastasis.

More about RhoVac